<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39336418</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>23</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Clinical Characteristics, Prognostic Factors, and Outcomes of COVID-19 in Autoimmune Rheumatic Disease Patients: A Retrospective Case-Control Study from Astana, Kazakhstan.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1377</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60091377</ELocationID><Abstract><AbstractText><i>Background:</i> Viral infections, including coronavirus disease 2019 (COVID-19), in patients with autoimmune rheumatic diseases (AIRDs) tend to present more severe disease. This study aims to investigate the clinical characteristics and risk factors for severe infection in rheumatologic patients. <i>Methods:</i> We included patients with a diagnosis of AIRD and COVID-19 infection between January 2022 and July 2023. Patients with AIRDs infected with SARS-CoV-2 were matched with control patients of the general population according to age (±5 years) and sex in a 1:1 ratio. Confirmed infection was defined if a patient had a positive polymerase chain reaction (PCR) test. The severity was divided into mild, moderate, severe, and critical according to the guidelines of the United States National Institutes of Health (NIH). <i>Results:</i> A total of 140 individuals (37 males, 103 females; mean age 56.1 ± 11.3 years) with rheumatic disease diagnosed with COVID-19 infection were enrolled in the study. AIRDs included rheumatoid arthritis (RA) (<i>n</i> = 63, 45%), ankylosing spondylitis (AS) (<i>n</i> = 35, 25%), systemic lupus erythematosus (SLE) (<i>n</i> = 26, 8.6%), and systemic sclerosis (SSc) (<i>n</i> = 16, 11.4%). The AIRDs group had more SARS-CoV-2-related dyspnea (38.6%), arthralgia (45.7%), and depression (27.1%) than the control group (<i>p</i> = 0.004). The rate of lung infiltration on radiographic examination was higher in 58 (41.4%, <i>p</i> = 0.005) patients with rheumatic diseases than in those without them. Severe SARS-CoV-2 infection was more common in the AIRDs group than in the control group (22% vs. 12%; <i>p</i> = 0.043). <i>Conclusions:</i> Patients with AIRDs experienced more symptoms of arthralgia, depression, and dyspnea. There was a trend towards an increased severity of the disease in patients with AIRDs. Patients with arterial hypertension, diabetes, chronic lung, and kidney disease, treated with corticosteroids, had a longer duration, and high activity of autoimmune disease had an increased risk of severe COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rutskaya-Moroshan</LastName><ForeName>Kristina</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-9324-8720</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisheva</LastName><ForeName>Saule</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6260-8220</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abisheva</LastName><ForeName>Anilim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amangeldiyeva</LastName><ForeName>Zhadra</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinnik</LastName><ForeName>Tatyana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biology, Ariel University, Ariel 40700, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batyrkhan</LastName><ForeName>Tansholpan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Family Medicine №1, NJSC «Astana Medical University», Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012216" MajorTopicYN="Y">Rheumatic Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007623" MajorTopicYN="N" Type="Geographic">Kazakhstan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 infection</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">disease course</Keyword><Keyword MajorTopicYN="N">disease-modifying antirheumatic drugs</Keyword><Keyword MajorTopicYN="N">prognostic factors</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336418</ArticleId><ArticleId IdType="pmc">PMC11433992</ArticleId><ArticleId IdType="doi">10.3390/medicina60091377</ArticleId><ArticleId IdType="pii">medicina60091377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 Cases|WHO COVID-19 Dashboard.  [(accessed on 29 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases.</Citation></Reference><Reference><Citation>Maddur M.S., Vani J., Lacroix-Desmazes S., Kaveri S., Bayry J. Autoimmunity as a Predisposition for Infectious Diseases. PLoS Pathog. 2010;6:e1001077. doi: 10.1371/journal.ppat.1001077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001077</ArticleId><ArticleId IdType="pmc">PMC2973828</ArticleId><ArticleId IdType="pubmed">21079687</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R., Lindhardsen J., Soussi B.G., Vela J., Uhrenholt L., Westermann R., Kristensen S., Nielsen H., Torp-Pedersen C., Dreyer L. Incidence and Severeness of COVID-19 Hospitalisation in Patients with Inflammatory Rheumatic Disease: A Nationwide Cohort Study from Denmark. Rheumatology. 2020;60:SI59–SI67. doi: 10.1093/rheumatology/keaa897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa897</ArticleId><ArticleId IdType="pmc">PMC7798558</ArticleId><ArticleId IdType="pubmed">33369663</ArticleId></ArticleIdList></Reference><Reference><Citation>Amigues I., Pearlman A.H., Patel A., Reid P., Robinson P.C., Sinha R., Kim A.H., Youngstein T., Jayatilleke A., Konig M. Coronavirus Disease 2019: Investigational Therapies in the Prevention and Treatment of Hyperinflammation. Expert. Rev. Clin. Immunol. 2020;16:1185–1204. doi: 10.1080/1744666X.2021.1847084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1847084</ArticleId><ArticleId IdType="pmc">PMC7879704</ArticleId><ArticleId IdType="pubmed">33146561</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., et al. Factors Associated with COVID-19-Related Death Using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M., Hyrich K.L., Al-Adely S., Carmona L., Danila M.I., Gossec L., Izadi Z., Jacobsohn L., Katz P., Lawson-Tovey S., et al. Characteristics Associated with Hospitalisation for COVID-19 in People with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Physician-Reported Registry. Ann. Rheum. Dis. 2020;79:859–866. doi: 10.1136/annrheumdis-2020-217871.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Clin. Infect. Dis. 2020;71:732–739. doi: 10.1093/cid/ciaa237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId><ArticleId IdType="pmc">PMC7108130</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S., Rosin N.L., Arora R., Labit E., Jaffer A., Cao L., Farias R., Nguyen A.P., de Almeida L.G.N., Dufour A., et al. Dexamethasone Modulates Immature Neutrophils and Interferon Programming in Severe COVID-19. Nat. Med. 2022;28:201–211. doi: 10.1038/s41591-021-01576-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01576-3</ArticleId><ArticleId IdType="pmc">PMC8799469</ArticleId><ArticleId IdType="pubmed">34782790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q., Lin H., Wei R.-G., Chen N., He F., Zou D.-H., Wei J.-R. Tocilizumab Treatment for COVID-19 Patients: A Systematic Review and Meta-Analysis. Infect. Dis. Poverty. 2021;10:71. doi: 10.1186/s40249-021-00857-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00857-w</ArticleId><ArticleId IdType="pmc">PMC8128625</ArticleId><ArticleId IdType="pubmed">34001244</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkotis G., Kitsou K., Xynogalas I., Spoulou V., Magiorkinis G., Trontzas I., Trontzas P., Poulakou G., Syrigos K., Bamias G. Systematic Review with Meta-Analysis: COVID-19 Outcomes in Patients Receiving Anti-TNF Treatments. Aliment. Pharmacol. Ther. 2022;55:154–167. doi: 10.1111/apt.16717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16717</ArticleId><ArticleId IdType="pubmed">34881430</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukusheva Z., Assylbekova M., Poddighe D. Management of pediatric rheumatic patients in Kazakhstan during the coronavirus disease 2019 (COVID-19) pandemic. Rheumatol. Int. 2020;40:1351–1352. doi: 10.1007/s00296-020-04613-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04613-5</ArticleId><ArticleId IdType="pmc">PMC7278260</ArticleId><ArticleId IdType="pubmed">32514608</ArticleId></ArticleIdList></Reference><Reference><Citation>Battakova Z., Imasheva B., Slazhneva T., Imashev M., Beloussov V., Pignatelli M., Tursynkhan A., Askarov A., Abdrakhmanova S., Adayeva A., et al. Public Health Response Measures for COVID-19 in Kazakhstan. Disaster Med. Public Health Prep. 2023;17:e524. doi: 10.1017/dmp.2023.181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/dmp.2023.181</ArticleId><ArticleId IdType="pubmed">37941110</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Strategic Planning and Reforms of the Republic of Kazakhstan Bureau of National Statistics—Main.  [(accessed on 29 June 2024)]; Available online:  https://stat.gov.kz/en/</Citation></Reference><Reference><Citation>Balakrishnan V.S. COVID-19 response in central Asia. Lancet Microbe. 2020;1:e281. doi: 10.1016/S2666-5247(20)30177-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30177-4</ArticleId><ArticleId IdType="pmc">PMC7832702</ArticleId><ArticleId IdType="pubmed">33521728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutskaya-Moroshan K., Abisheva S., Sarsenova M., Ogay V., Vinnik T., Aubakirova B., Abisheva A. Autoimmune Rheumatic Diseases and COVID-19 Vaccination: A Retrospective Cross-Sectional Study from Astana. Reumatologia. 2024;62:26–34. doi: 10.5114/reum/184335.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum/184335</ArticleId><ArticleId IdType="pmc">PMC10979372</ArticleId><ArticleId IdType="pubmed">38558898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Liu J., Shao R., Han X., Su C., Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and meta-analysis. Rheumatol. Int. 2021;41:851–861. doi: 10.1007/s00296-021-04803-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04803-9</ArticleId><ArticleId IdType="pmc">PMC7941871</ArticleId><ArticleId IdType="pubmed">33687528</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahendra M., Nuchin A., Kumar R., Shreedhar S., Mahesh P.A. Predictors of mortality in patients with severe COVID-19 pneumonia—A retrospective study. Adv. Respir. Med. 2021;89:135–144. doi: 10.5603/arm.a2021.0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/arm.a2021.0036</ArticleId><ArticleId IdType="pubmed">33966261</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Flook M., Jackson C., Vasileiou E., Simpson C.R., Muckian M.D., Agrawal U., McCowan C., Jia Y., Murray J.L.K., Ritchie L.D., et al. Informing the public health response to COVID-19: A systematic review of risk factors for disease, severity, and mortality. BMC Infect. Dis. 2021;21:342. doi: 10.1186/s12879-021-05992-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-05992-1</ArticleId><ArticleId IdType="pmc">PMC8040367</ArticleId><ArticleId IdType="pubmed">33845766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelsey J.L., Evans A.S., Alice S. Methods in Observational Epidemiology. 2nd ed. Oxford University Press; Oxford, UK: 1996.</Citation></Reference><Reference><Citation>Fleiss, Statistical Methods for Rates and Proportions, Formulas 3.18 &amp;3.19. John Wiley &amp; Sons; Hoboken, NJ, USA: 2003.</Citation></Reference><Reference><Citation>Wang F., Ma Y., Xu S., Liu H., Chen Y., Yang H., Shao M., Xu W., Kong J., Chen L., et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin. Rheumatol. 2022;41:2213–2223. doi: 10.1007/s10067-022-06087-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06087-1</ArticleId><ArticleId IdType="pmc">PMC8964246</ArticleId><ArticleId IdType="pubmed">35352217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W., Chen X., Ho D.C.W., Wang H. Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: A nationwide cohort study. Lancet Rheumatol. 2021;3:e698–e706. doi: 10.1016/S2665-9913(21)00151-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00151-X</ArticleId><ArticleId IdType="pmc">PMC8213376</ArticleId><ArticleId IdType="pubmed">34179832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Yi Z., Cai R., Chen R., Thong B.Y., Mu R. Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. Autoimmun. Rev. 2021;20:102778. doi: 10.1016/j.autrev.2021.102778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102778</ArticleId><ArticleId IdType="pmc">PMC7889462</ArticleId><ArticleId IdType="pubmed">33609804</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Gao Y., Zhang Y., Shi S., Chen Y., Tian J. The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta analysis. J. Infect. 2020;81:e93–e95. doi: 10.1016/j.jinf.2020.05.065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.05.065</ArticleId><ArticleId IdType="pmc">PMC7264926</ArticleId><ArticleId IdType="pubmed">32502509</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz D.A., Fahmy T.M., Piccirillo C.A., La Cava A. Rebalancing Immune Homeostasis to Treat Autoimmune Diseases. Trends Immunol. 2019;40:888–908. doi: 10.1016/j.it.2019.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.08.003</ArticleId><ArticleId IdType="pmc">PMC7136015</ArticleId><ArticleId IdType="pubmed">31601519</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadras O., Afsahi A.M., Pashaei Z., Mojdeganlou H., Karimi A., Habibi P., Barzegary A., Fakhfouri A., Mirzapour P., Janfaza N., et al. The relationship between COVID-19 viral load and disease severity: A systematic review. Immun. Inflamm. Dis. 2022;10:e580. doi: 10.1002/iid3.580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.580</ArticleId><ArticleId IdType="pmc">PMC8926507</ArticleId><ArticleId IdType="pubmed">34904379</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Shen G., Yang H., Huang A., Chen X., Dong L., Wu B., Zhang A., Su L., Hou X., et al. COVID-19 in patients with rheumatic disease in Hubei province, China: A multicentre retrospective observational study. Lancet Rheumatol. 2020;2:e557–e564. doi: 10.1016/S2665-9913(20)30227-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30227-7</ArticleId><ArticleId IdType="pmc">PMC7333992</ArticleId><ArticleId IdType="pubmed">32838309</ArticleId></ArticleIdList></Reference><Reference><Citation>Strangfeld A., Schäfer M., Gianfrancesco M.A., Lawson-Tovey S., Liew J.W., Ljung L., Mateus E.F., Richez C., Santos M.J., Schmajuk G., et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2021;80:930–942. doi: 10.1136/annrheumdis-2020-219498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-219498</ArticleId><ArticleId IdType="pmc">PMC7843211</ArticleId><ArticleId IdType="pubmed">33504483</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway R., Grimshaw A., Konig M., Putman M., Duarte-García A., Tseng L., Cabrera D., Chock Y., Degirmenci H., Duff E., et al. SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. Arthritis Rheumatol. 2022;74:766–775. doi: 10.1002/art.42030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42030</ArticleId><ArticleId IdType="pmc">PMC9011807</ArticleId><ArticleId IdType="pubmed">34807517</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastelum-Strozzi A., Pascual V., Hernández-Garduño A., Moctezuma-Rios J.F., Guaracha-Basañez G.A., Sotelo T., Garcia-Garcia C., Contreras-Yañez I., Álvarez-Hernández E., Infante-Castañeda C., et al. Perception of risk and impact of the COVID-19 pandemic on patients with rheumatic diseases: A case-control study. Clin. Rheumatol. 2022;41:3211–3218. doi: 10.1007/s10067-022-06257-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-022-06257-1</ArticleId><ArticleId IdType="pmc">PMC9255952</ArticleId><ArticleId IdType="pubmed">35790594</ArticleId></ArticleIdList></Reference><Reference><Citation>Outcomes Following SARS-CoV-2 Infection in Individuals with and without Inflammatory Rheumatic Diseases: A Danish Nationwide Cohort Study|Annals of the Rheumatic Diseases.  [(accessed on 29 June 2024)].  Available online:  https://ard.bmj.com/content/82/10/1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">37414519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rorat M., Zarębska-Michaluk D., Kowalska J., Kujawa K., Rogalska M., Kozielewicz D., Lorenc B., Sikorska K., Czupryna P., Bolewska B., et al. The Course of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases. J. Clin. Med. 2022;11:7342. doi: 10.3390/jcm11247342.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247342</ArticleId><ArticleId IdType="pmc">PMC9781406</ArticleId><ArticleId IdType="pubmed">36555957</ArticleId></ArticleIdList></Reference><Reference><Citation>Pablos J.L., Galindo M., Carmona L., Lledó A., Retuerto M., Blanco R., Gonzalez-Gay M.A., Martinez-Lopez D., Castrejón I., Alvaro-Gracia J.M., et al. Clinical Outcomes of Hospitalised Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases: A Multicentric Matched Cohort Study. Ann. Rheum. Dis. 2020;79:1544–1549. doi: 10.1136/annrheumdis-2020-218296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218296</ArticleId><ArticleId IdType="pubmed">32796045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastritis E., Kitas G.D., Vassilopoulos D., Giannopoulos G., Dimopoulos M.A., Sfikakis P.P. Systemic Autoimmune Diseases, Anti-Rheumatic Therapies, COVID-19 Infection Risk and Patient Outcomes. Rheumatol. Int. 2020;40:1353–1360. doi: 10.1007/s00296-020-04629-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04629-x</ArticleId><ArticleId IdType="pmc">PMC7353833</ArticleId><ArticleId IdType="pubmed">32654078</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikuls T.R., Johnson S.R., Fraenkel L., Arasaratnam R.J., Baden L.R., Bermas B.L., Chatham W., Cohen S., Costenbader K., Gravallese E.M., et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2020;72:e1–e12. doi: 10.1002/art.41437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41437</ArticleId><ArticleId IdType="pubmed">32734689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nas K., Güçlü E., Keskin Y., Dilek G., Kalçık Unan M., Can N., Tekeoğlu İ., Kamanlı A. Clinical Course and Prognostic Factors of COVID-19 Infection in Patients with Chronic Inflammatory-Rheumatic Disease: A Retrospective, Case-Control Study. Arch. Rheumatol. 2023;38:44–55. doi: 10.46497/ArchRheumatol.2023.9289.</Citation><ArticleIdList><ArticleId IdType="doi">10.46497/ArchRheumatol.2023.9289</ArticleId><ArticleId IdType="pmc">PMC10208609</ArticleId><ArticleId IdType="pubmed">37235113</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.C., Yazdany J. The COVID-19 Global Rheumatology Alliance: Collecting data in a pandemic. Nat. Rev. Rheumatol. 2020;16:293–294. doi: 10.1038/s41584-020-0418-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0418-0</ArticleId><ArticleId IdType="pmc">PMC7117553</ArticleId><ArticleId IdType="pubmed">32242121</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez A.I., Labandeira C.M., Pedrosa M.A., Valenzuela R., Suarez-Quintanilla J.A., Cortes-Ayaso M., Mayán-Conesa P., Labandeira-Garcia J.L. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J. Autoimmun. 2021;122:102683. doi: 10.1016/j.jaut.2021.102683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102683</ArticleId><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Briquez P.S., Rouhani S.J., Yu J., Pyzer A.R., Trujillo J., Dugan H.L., Stamper C.T., Changrob S., Sperling A.I., Wilson P.C., et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci. Adv. 2022;8:eabn3777. doi: 10.1126/sciadv.abn3777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn3777</ArticleId><ArticleId IdType="pmc">PMC9544317</ArticleId><ArticleId IdType="pubmed">36206332</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberman R.H., Castillo R., Chen A., Yan D., Ramirez D., Sekar V., Lesser R., Solomon G., Neimann A.L., Blank R.B., et al. COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arthritis Rheumatol. 2020;72:1981–1989. doi: 10.1002/art.41456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41456</ArticleId><ArticleId IdType="pmc">PMC7722024</ArticleId><ArticleId IdType="pubmed">32725762</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.C., Morand E. Divergent Effects of Acute versus Chronic Glucocorticoids in COVID-19. Lancet Rheumatol. 2021;3:e168–e170. doi: 10.1016/S2665-9913(21)00005-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00005-9</ArticleId><ArticleId IdType="pmc">PMC7833899</ArticleId><ArticleId IdType="pubmed">33521656</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca D.L.M., Filgueiras I.S., Marques A.H.C., Vojdani E., Halpert G., Ostrinski Y., Baiocchi G.C., Plaça D.R., Freire P.P., Pour S.Z., et al. Severe COVID-19 patients exhibit elevated levels of autoantibodies targeting cardiolipin and platelet glycoprotein with age: A systems biology approach. NPJ Aging. 2023;9:21. doi: 10.1038/s41514-023-00118-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41514-023-00118-0</ArticleId><ArticleId IdType="pmc">PMC10449916</ArticleId><ArticleId IdType="pubmed">37620330</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson A., Wilkinson T.M.A. Respiratory viral infections in the elderly. Ther. Adv. Respir. Dis. 2021;15:1753466621995050. doi: 10.1177/1753466621995050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753466621995050</ArticleId><ArticleId IdType="pmc">PMC7989115</ArticleId><ArticleId IdType="pubmed">33749408</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med. Virol. 2021;93:1449–1458. doi: 10.1002/jmv.26424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26424</ArticleId><ArticleId IdType="pmc">PMC7436673</ArticleId><ArticleId IdType="pubmed">32790106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijls B.G., Jolani S., Atherley A., Derckx R.T., Dijkstra J.I.R., Franssen G.H.L., Hendriks S., Richters A., Venemans-Jellema A., Zalpuri S., et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open. 2021;11:e044640. doi: 10.1136/bmjopen-2020-044640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-044640</ArticleId><ArticleId IdType="pmc">PMC7802392</ArticleId><ArticleId IdType="pubmed">33431495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lassale C., Gaye B., Hamer M., Gale C.R., Batty G.D. Ethnic disparities in hospitalisation for COVID-19 in England: The role of socioeconomic factors, mental health, and inflammatory and pro-inflammatory factors in a community-based cohort study. Brain Behav. Immun. 2020;88:44–49. doi: 10.1016/j.bbi.2020.05.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.074</ArticleId><ArticleId IdType="pmc">PMC7263214</ArticleId><ArticleId IdType="pubmed">32497776</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B., Ng F., Nguyen T. High Mortality from COVID-19 among Asian Americans in San Francisco. Asian American Research Center on Health. 2020.  [(accessed on 20 April 2024)].  Available online:  https://scholar.google.com/citations?view_op=view_citation&amp;hl=en&amp;user=SbnK3p8AAAAJ&amp;citation_for_view=SbnK3p8AAAAJ:eQOLeE2rZwMC.</Citation></Reference><Reference><Citation>Gianfrancesco M.A., Leykina L.A., Izadi Z., Taylor T., Sparks J.A., Harrison C., Trupin L., Rush S., Schmajuk G., Katz P., et al. Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021;73:374–380. doi: 10.1002/art.41567.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41567</ArticleId><ArticleId IdType="pmc">PMC8467766</ArticleId><ArticleId IdType="pubmed">33146001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce B., Fries J.F., Murtagh K.N. Health status disparities in ethnic minority patients with rheumatoid arthritis: A cross-sectional study. J. Rheumatol. 2007;34:1475–1479.</Citation><ArticleIdList><ArticleId IdType="pubmed">17552045</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg J.D., Spruill T.M., Shan Y., Reed G., Kremer J.M., Potter J., Yazici Y., Ogedegbe G., Harrold L.R. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am. J. Med. 2013;126:1089–1098. doi: 10.1016/j.amjmed.2013.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2013.09.002</ArticleId><ArticleId IdType="pmc">PMC4006346</ArticleId><ArticleId IdType="pubmed">24262723</ArticleId></ArticleIdList></Reference><Reference><Citation>FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann. Rheum. Dis. 2021;80:527–538. doi: 10.1136/annrheumdis-2020-218310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218310</ArticleId><ArticleId IdType="pmc">PMC7712850</ArticleId><ArticleId IdType="pubmed">33268442</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J.M., Faruqi A.J., Sullivan J.K., Calabrese C., Calabrese L.H. COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review. Pathog. Immun. 2021;6:76–103. doi: 10.20411/pai.v6i1.435.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v6i1.435</ArticleId><ArticleId IdType="pmc">PMC8150936</ArticleId><ArticleId IdType="pubmed">34056149</ArticleId></ArticleIdList></Reference><Reference><Citation>Loarce-Martos J., García-Fernández A., López-Gutiérrez F., García-García V., Calvo-Sanz L., del Bosque-Granero I., Terán-Tinedo M.A., Boteanu A., Bachiller-Corral J., Vázquez-Díaz M. High Rates of Severe Disease and Death Due to SARS-CoV-2 Infection in Rheumatic Disease Patients Treated with Rituximab: A Descriptive Study. Rheumatol. Int. 2020;40:2015–2021. doi: 10.1007/s00296-020-04699-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04699-x</ArticleId><ArticleId IdType="pmc">PMC7499013</ArticleId><ArticleId IdType="pubmed">32945944</ArticleId></ArticleIdList></Reference><Reference><Citation>Tepasse P.-R., Hafezi W., Lutz M., Kühn J., Wilms C., Wiewrodt R., Sackarnd J., Keller M., Schmidt H.H., Vollenberg R. Persisting SARS-CoV-2 Viraemia after Rituximab Therapy: Two Cases with Fatal Outcome and a Review of the Literature. Br. J. Haematol. 2020;190:185–188. doi: 10.1111/bjh.16896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16896</ArticleId><ArticleId IdType="pmc">PMC7300950</ArticleId><ArticleId IdType="pubmed">32557623</ArticleId></ArticleIdList></Reference><Reference><Citation>Leipe J., Wilke E.L., Ebert M.P., Teufel A., Reindl W. Long, Relapsing, and Atypical Symptomatic Course of COVID-19 in a B-Cell-Depleted Patient after Rituximab. Semin. Arthritis Rheum. 2020;50:1087–1088. doi: 10.1016/j.semarthrit.2020.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.06.013</ArticleId><ArticleId IdType="pmc">PMC7833880</ArticleId><ArticleId IdType="pubmed">32916559</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeigue P.M., Porter D., Hollick R.J., Ralston S.H., McAllister D.A., Colhoun H.M. Risk of Severe COVID-19 in Patients with Inflammatory Rheumatic Diseases Treated with Immunosuppressive Therapy in Scotland. Scand. J. Rheumatol. 2023;52:412–417. doi: 10.1080/03009742.2022.2063376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2022.2063376</ArticleId><ArticleId IdType="pubmed">35549809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y.-D., Ding M., Dong X., Zhang J.-J., Kursat Azkur A., Azkur D., Gan H., Sun Y.-L., Fu W., Li W., et al. Risk Factors for Severe and Critically Ill COVID-19 Patients: A Review. Allergy. 2021;76:428–455. doi: 10.1111/all.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>